Luminary Group’s Post

At the ongoing ASCO 2024, Merck Group showcased the Phase I trial data evaluating MK-0482. MK-0482 is a novel humanized IgG4 monoclonal antibody that targets ILT3, potentially alleviating immunosuppression within the tumor microenvironment. In the expansion cohort of the first-in-human Phase I study (MK-0482-001), the combination of MK-0482, #pembrolizumab, and #gemcitabine/nab-paclitaxel was evaluated in patients with treatment-naive metastatic pancreatic ductal adenocarcinoma. Experience Expert Insights and Comprehensive Analysis with DelveInsight Business Research LLP's Special American Society of Clinical Oncology (ASCO) 2024 Coverage: https://lnkd.in/g-BfAdn4 #ASCO24 #CancerTreatment #ASCO2024 #LungCancer #NSCLC #mCRPC #PharmaInnovation #MedicalResearch #OncologyAdvancements #ClinicalOncology #Pharmaceuticals #HealthcareConference #CancerResearch #ClinicalPractice #MedicalBreakthroughs #CancerCare #PharmaLeaders

At the ongoing American Society of Clinical Oncology (ASCO) 2024, Merck Group showcased the Phase I trial data evaluating MK-0482. MK-0482 is a novel humanized IgG4 monoclonal antibody that targets ILT3, potentially alleviating immunosuppression within the tumor microenvironment. In the expansion cohort of the first-in-human Phase I study (MK-0482-001), the combination of MK-0482, pembrolizumab, and gemcitabine/nab-paclitaxel was evaluated in patients with treatment-naive metastatic pancreatic ductal adenocarcinoma. Experience Expert Insights and Comprehensive Analysis with DelveInsight Business Research LLP's Special ASCO 2024 Coverage: https://lnkd.in/gnrRB-5B #ASCO24 #CancerTreatment #ASCO2024 #LungCancer #NSCLC #mCRPC #PharmaInnovation #MedicalResearch #OncologyAdvancements #ClinicalOncology #Pharmaceuticals #HealthcareConference #CancerResearch #ClinicalPractice #MedicalBreakthroughs #CancerCare #PharmaLeaders

Today is #WorldAtopicEczemaDay, a day dedicated to bringing awareness to one of the most prevalent skin diseases, affecting over 30 million people in the United States.    At RAPT, we’re using our science to explore ways to overcome inflammation, including eczema (atopic dermatitis).   Explore how RPT193 – our oral, small molecule, CCR4 inhibitor – has potential in eczema by watching a video on how it works here: https://lnkd.in/g5D8UKVg

As promised, here is a new blog post unpacking what we know so far about the design of Ionis's upcoming PrProfile trial of ION717 in prion disease: https://lnkd.in/gfRrG3ex

“Screening of parents is very important for the prevention of this disease.” September is marked as Sickle Cell Disease Awareness Month. In this video, Dr. (Col.) Tarun Verma (Senior Consultant, Haematology & Haemato-Oncology) talks all about sickle cell disease - what it is and the line of treatment that can be followed. Do watch this informative video and also share it with your dear ones. #SickleCellDiseaseAwarenessMonth #SickleCellAwareness #sicklecell #sicklecelldisease #yashodahealthcare

First Randomized Controlled Trial Showing Non-Pharma Intervention (Lifestyle Changes) Can Help Reduce Alzheimer’s Disease SymptomsFirst Randomized Controlled Trial Showing Non-Pharma Intervention (Lifestyle Changes) Can Help Reduce Alzheimer’s Disease Symptoms https://lnkd.in/e38a5Wdy

Starting the day with great news for the Rare Disease Community! “X4's mavorixafor, which will be sold under the brand name Xolremdi, is the first therapy to get U.S. approval specifically for the treatment of WHIM syndrome. WHIM is characterized by disorders in which the body's immune system does not function properly. It is an acronym for warts, hypogammaglobulinemia or low antibody levels, infections, and myelokathexis or low white blood cell count, which are all symptoms of the disorder.” https://lnkd.in/gb87WUHk #FDAapproval #RareDisease #MedicalAffairs #MSL #MedicalScienceLiaison

Lilly’s donanemab was approved recently by the US FDA for early symptomatic Alzheimer’s disease. Looking forward to longer-term data in real-world settings and results from ongoing trial with Lilly’s another potential amyloid-targeting therapeutic for Alzheimer’s disease, remternetug. Here is an interesting short read on donanemab’s target - https://lnkd.in/dQPt-_Re

let us discuss VKH in 6 questions 6 Questions on _VKH Disease_ to be answered in 90 minutes* Question 1: What are the management options in VKH Disease ? Question 2 : Is the patient with angle closure; that you are currently treating, actually VKH Disease ? Question 3: What are the classification criteria for VKH Disease ? Question 4: Is there a role of biologics in VKH Disease ? Question 5: Is there ever a battle between immune support and immunosuppression ? Question 6: Does VKH Disease have more than one face ? Learn about *VKH Disease* from the experts *tomorrow between 11:00 am - 12:30 pm* https://lnkd.in/gnvJJyne

Dry Eye Disease news and information breaks at the speed of light these days. The best place to keep up with all things "DED" is at our Dry Eye Topic Resource Centers! https://lnkd.in/eefWsATD https://lnkd.in/ektYcCW3 #Ophthalmology #Optometry #DryEyeDisease